Identification of PI3K/AKT/mTOR-related genes as diagnostic biomarkers for cutaneous squamous cell carcinoma
Bingyan Yang1, Hongyang Zhang1, Lingdi Dong1
1Department of Dermatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Background:
Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer. Considering the substantial improvement in prognosis when detected at an early stage, identifying biomarkers for an early diagnosis of cSCC is crucial. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway plays a crucial role in cSCC progression; This study aimed to identify PI3K/AKT/mTOR-related genes that may serve as diagnostic indicators for cSCC, thereby providing a diagnostic framework for this disease.
Methods/Results:
A total of 33 PI3K/AKT/mTOR-related differentially expressed genes (DEGs) in cSCC were acquired by intersecting the DEGs from the Gene Expression Omnibus database between normal and cSCC groups and genes reported to be associated with the PI3K/AKT/mTOR pathway in the literature. LASSO regression identified 11 hub genes (AKT1, AKT3, EIF4EBP1, GFRA1, GRSF1, HIF1A, IGF1, IL11, IL24, KRT75, and MMP3), which were used to construct the diagnostic model. Receiver operating curve analysis revealed that these hub genes displayed strong diagnostic capacity. Quantitative polymerase chain reaction validation confirmed significant differences in mRNA expression of HIF1A, MMP3, IL11, GRSF1, and EIF4EBP1 between cSCC and normal cell lines.
Conclusion:
These five PI3K/AKT/mTOR-related genes have the potential to serve as clinical biomarkers for the diagnosis of cSCC and as candidate therapeutic targets. This study offers valuable insights for further research to elucidate the specific pathological mechanisms and establish innovative treatment approaches for cSCC.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The JAK-STAT Signaling Pathway


